Joint Conference of European Human Pharmacological Societies CLUB PHASE I (France), AGAH (Germany), BAPU (Belgium), AHPPI (UK)

Posted:
28
February 2013

Please join us at theJoint Conference of European Human Pharmacological Societies CLUB PHASE I (France), AGAH (Germany), BAPU (Belgium), AHPPI (UK)11 & 12 April 2013Nice Sophia Antipolis, FranceThe meeting will focus on Early Clinical Utility Assessment of new medicines and how early development should be conducted to optimize the challenging process of reaching efficient and early go/no go decisions.Be part of this European meeting featuring first class plenary sessions and interactive workshops and experience excellent networking opportunities in stimulating surroundings.View programmeRegister online

Please forward this invitation to interested colleagues also.Looking forward to seeing you!Sincerely yoursConference ChairDr. Yves DonazzoloPresident CLUB PHASE IIntercom Kongresse GmbHAntje BlmekeEppendorfer Baum 39a20249 Hamburg (Germany)Phone: +49 40 480610 61Telefax: +49 40 480610 66E-Mail: abloemeke@intercom.deWeb: www.intercom..de

Disclaimer 2013 Intercom Kongresse GmbHEppendorfer Baum 39a, 20249 Hamburg/GermanyUSt-ID DE 1615 400 24, Registry court Hamburg, HRB 113503. All rights reserved. Responsible for contents pursuant to 6 MDStV Managing Director Alexandra Werner.

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021
J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.
Read more

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021
Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.
Read more